Success Metrics

Clinical Success Rate

93.9%

Based on 31 completed trials

Completion Rate

94%(31/33)

Active Trials

2(5%)

Results Posted

68%(21 trials)

Terminated

2(5%)

Phase Distribution

Ph not_applicable

Ph phase_1

Ph phase_3

46%

Ph phase_2

Ph phase_4

24%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution32 total trials

Phase 1Safety & dosage

3(9.4%)

Phase 2Efficacy & side effects

2(6.3%)

Phase 3Large-scale testing

17(53.1%)

Phase 4Post-market surveillance

9(28.1%)

N/ANon-phased studies

1(3.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.2%

31 of 34 finished

Non-Completion Rate

8.8%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(31)

Terminated(3)

Other(1)

Detailed Status

Completed31

Terminated2

Active, not recruiting1

unknown1

Withdrawn1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

93.9%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (9.4%)

Phase 22 (6.3%)

Phase 317 (53.1%)

Phase 49 (28.1%)

N/A1 (3.1%)

Trials by Status

terminated25%

active_not_recruiting13%

unknown13%

completed3184%

withdrawn13%

recruiting13%

Recent Activity

2 active trials

Showing 5 of 37

active_not_recruitingphase_4

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

NCT02731612

completedphase_2

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

NCT03557931

View all 37 trials

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more

NCT06433635Phase 4

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

Active Not Recruiting

NCT06328140

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

Withdrawn

NCT01569659Phase 4

High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

Completed

NCT02731612Phase 3

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

Completed

NCT03557931Phase 2

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Completed

NCT06527885

Lurasidone Non-Interventional Study in Schizophrenia Patients

Completed

NCT05213143Phase 4

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

Terminated

NCT05011669Phase 4

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

Completed

NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

NCT03902613Phase 4

18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder

Completed

NCT04312503

Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

Completed

NCT05351736Phase 4

Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)

Unknown

NCT05480150Not Applicable

Chinese Longitudinal and Systematic Study of Bioplar Disorder

Recruiting

NCT01498770

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

Completed

NCT02199743Phase 4

Lurasidone Effects on Tissue Glutamate in Schizophrenia

Completed

NCT03304457Phase 4

Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia

Completed

NCT03393026Phase 4

A Study of Lurasidone HCl in Subjects With Schizophrenia

Completed

NCT01566162Phase 3

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Completed

NCT02046369Phase 3

Lurasidone Pediatric Bipolar Study

Completed

NCT02147379Phase 3

Lurasidone and Cognition in Bipolar I Disorder

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 37